APA (7th ed.) Citation

C, F., L, M., O, C., I, A., B, D., & S, F. (2025). Subcutaneous rituximab in indolent primary cutaneous B cell lymphoma: A case series of 5 patients with the evaluation of the medico economic impact. Therapie, 80(5), 619. https://doi.org/10.1016/j.therap.2025.04.001

Chicago Style (17th ed.) Citation

C, Fassanaro, Mortier L, Carpentier O, Arib I, Dervaux B, and Faiz S. "Subcutaneous Rituximab in Indolent Primary Cutaneous B Cell Lymphoma: A Case Series of 5 Patients with the Evaluation of the Medico Economic Impact." Therapie 80, no. 5 (2025): 619. https://doi.org/10.1016/j.therap.2025.04.001.

MLA (9th ed.) Citation

C, Fassanaro, et al. "Subcutaneous Rituximab in Indolent Primary Cutaneous B Cell Lymphoma: A Case Series of 5 Patients with the Evaluation of the Medico Economic Impact." Therapie, vol. 80, no. 5, 2025, p. 619, https://doi.org/10.1016/j.therap.2025.04.001.